Host cell proteins (HCPs) are process-related impurities generated during biotherapeutic protein production. HCPs can be problematic if they pose a significant metabolic demand, degrade product quality, or contaminate the final product. Here, we present an effort to create a "clean" Chinese hamster ovary (CHO) cell by disrupting multiple genes to eliminate HCPs. Using a model of CHO cell protein secretion, we predicted the elimination of unnecessary HCPs could have a non-negligible impact on protein production. We analyzed the total HCP content of 6-protein, 11-protein, and 14-protein knockout clones and characterized their growth in shake flasks and bioreactors. These cell lines exhibited a substantial reduction in total HCP content (40%-70%). We also observed higher productivity and improved growth characteristics, in specific clones. With the reduced HCP content, protein A and ion exchange chromatography more efficiently purified a
Introduction
Host cell proteins (HCPs) that are released from dead cells and secreted from viable cells accumulate extracellularly during mammalian cell culture, potentially impairing product quality 1, 2 and posing an immunogenic risk factor 3 . HCPs must be reduced to low levels (less than 1-100 ppm) in all cell-derived protein biotherapeutics before final product formulation, putting a great demand on downstream purification. Depending on titer, downstream processing comprises up to 80% of the entire production costs of a monoclonal antibody (mAb) 4 . In the production of a mAb, protein A affinity capture is often employed as a generic first step, followed by two or three orthogonal polishing steps 5 .
Although the concentrations of HCPs in cell culture harvests are reduced to acceptable levels after these purification steps, certain HCPs can escape an entire purification process and remain in the final product at levels that may affect product quality and stability, cause an immunogenic reaction, or display residual activity 6, 7 . It is therefore of utmost importance to closely monitor and identify HCPs to ensure their removal from biotherapeutic products. Enzyme-linked immunosorbent assay (ELISA) is typically used in industrial processes to monitor the total HCP content, but gives no information on specific Preparation and deep sequencing were carried out on a MiSeq Benchtop Sequencer (Illumina, San Diego, CA). The protocol for amplifying the CRISPR-targeted genomic sequences, amplicon purification, adapter-PCR and quality analysis followed our previously published methods 14 .
Generation of antibody expressing cell lines
WT and knockout cell lines (6xKO, 11xKO and 14xKO) were initiated from cryopreserved vials and passaged for one week prior to transfection. Transfection efficiency was determined by transfecting the pMAX-GFP (Lonza) and subsequent FACS analysis. Cells were transfected with a plasmid encoding the antibody Rituximab and the zeocin selection gene using Freestyle MAX reagent, following the manufacturer's recommendations and maintained for two days before selection pressure was initiated with zeocin (400 µg/mL).
After 21 days of selection, viability was above 95% in all cultures and pools were stored in vials containing 10% DMSO. To enrich for clones with high productivity, immunostaining of Rituximab on the plasma membrane (surface staining) was performed on the Rituximab expressing cell pool by staining with an anti-human IgG antibody conjugated to FITC (Invitrogen, Carlsbad, CA, USA) and subsequent single-cell sorting using fluorescence activated cell sorting (FACS) and expansion. To select clones with the highest productivity, we used the titer-to-confluency method 18 . 
Mass spectrometry identification of HCPs
WT CHO-S was cultivated in duplicate in three separate DASGIP Mini bioreactor experiments. HCCF was obtained during late exponential phase by centrifugation at 500g for 10 minutes. Samples were TCA-precipitated with an overnight incubation in ice cold acetone, and the dry protein pellet was dissolved in 100 µl 8M urea. Samples were treated first with 100 mM DTT (5 µl) and incubated at 37°C for 45 minutes and then with 100 mM iodoacetamide (10 µl) and incubated in the dark for 45 minutes. Samples containing 100 µg of protein were digested overnight at 37°C using trypsin after which 10% TFA was added, and samples were stage tipped. Data were acquired on Synapt G2 (Waters) Q-TOF instrument operated in positive mode using ESI with a NanoLock-spray source.
During MS E acquisition, the mass spectrometer alternated between low and high energy mode using a scan time of 0.8 s for each mode over a 50-2000 Da interval. Nanoscale LC separation of the tryptic digested samples was performed using a nanoAcquity system (Waters, Milford, MA, USA) equipped a nanoAcquity BEH130 C18 1.7 µm, 75 µm x 250 mm analytical reversed-phase column (Waters). A reversed-phase gradient was employed to separate peptides using 5-40% acetonitrile in water over 90 min with a flow rate of 250 nL/min and a column temperature of 35°C. The data were analyzed using the progenesis QI software (NonLinear dynamics), which aligns the different runs ensuring that the precursor ions and identifications can be shared in between runs.
HCP, antibody and protein quantification
All quantification was performed using biolayer interferometry on an Octet RED96 (Pall, HCCF was TCA-precipitated, and whole cells were lysed using RIPA buffer.
Protein purification
Cell-free supernatants were prepared by centrifugation and directly loaded (100 mL) onto 
Results

CHO cells spend substantial resources on the host cell secretome
There are several potential advantages to the removal of HCPs, including the elimination of immunogenic proteins or proteins that degrade product quality. However, the question remains regarding the bioenergetic investment made by the host cells on the secreted fraction of their proteome. To evaluate the resource and bioenergetic investment of CHO cells into their secretome, we calculated the cost of each protein using a model of CHO cell protein secretion 19 , scaled by its expression in RNA-Seq data 20 . In CHO-S cells, we found that 39.2% of the resources are dedicated to producing membrane and secreted proteins, most of which are processed through the secretory pathway (Fig. 1A) . 10.2% of the cell resources were explicitly dedicated to secreted proteins with signal peptides, and a relatively small number of secreted proteins account for the majority of the bioenergetic cost and use of the secretory pathway. Furthermore, we anticipate that the cost for secreted proteins is likely higher since these proteins are not turned over and recycled like intracellular and membrane proteins. Thus, there is great potential to free up cellular resources and secretory capacity, in addition to improving product quality by eliminating unnecessary HCPs. Following proteomic analysis of the HCCF, 14 proteins (associated with 13 gene loci) were identified and targeted for deletion. We quantified the bioenergetic cost of protein synthesis and secretion in CHO cells, and we found the deletion of the target genes will free up significantly more bioenergetic resources than expected from the deletion of a similar number of randomly selected genes. RPM = reads mapping to gene per million reads in the transcriptome.
Target selection and verification
To decrease HCP secretion and free up resources for CHO cell growth and protein production, we identified targets based on three criteria: (i) being abundant in CHO supernatants as analyzed by mass spectrometry (Table S1 ), (ii) being a difficult-to-remove impurity in downstream processing [22] [23] [24] [25] , and (iii) having a negative impact on product quality 1, 26, 27 . To remove the genes, we subjected the cell lines in this study to 4 cycles of CRISPR/Cas9-mediated multiplex gene disruption. In the first round, the gene encoding
Metalloproteinase inhibitor 1 (Timp1) was disrupted. In the second round, the genes encoding Biglycan (BGN), Galectin-3-binding protein (LGALS3BP), Nidogen-1 (NID1.1 and NID1.2), and Cathepsin D (CTSD) were disrupted, resulting in the 6xKO cell line. In the Table 1 . Selection and MiSeq verification of knockout targets addressed in this study. The target genes names, protein names, UniProt identifiers, rationale for deletion, subcellular location, and indel size are indicated. For rationale: A, abundance; C, copurifying; Q, quality.
Cell line Target Protein name Uniprot Rationale Location Frameshift
LGALS3BP Galectin-3-binding protein G3H3E4 A/C Membrane +33 The targets were predominantly identified through proteomics on spent media or purified product, and we verified that these genes were, on average among the more abundant transcripts for secreted proteins, and accounted for proteins exerting a greater cost to the cell (Fig. 1B) . Furthermore, upon quantifying the amount of ATP liberated upon their deletion, we found their deletion led to a significantly higher amount of resources eliminated (p << 1x10 -5 ), when compared to a comparable number of randomly selected genes.
We verified gene disruption at the genomic and proteomic levels. Specifically, we used MiSeq analysis ( Table 1 ) to verify that all indels led to frameshift mutations except for the one generated in LGALS3BP, which leads to a partly scrambled amino acid sequence and the introduction of a stop codon after residue 44. Mass spectrometry was subsequently used to verify the absence of our target proteins after gene disruption. Supernatants from To assess the properties of our knockout cell lines, we followed their growth and viability for 7 days in shake flasks with daily sampling to measure viable cell density (VCD), cell viability, and HCP content (Fig. 3) . Interestingly, cell density and viability of knockout cell lines were improved over WT (Fig. 3A) . While the 6xKO cell VCD of the knockout cell lines is higher, the behavior of the cell lines can arguably better be described by calculating specific HCP productivities. Specific HCP productivity was found to be 13.5 picograms per cell per day (pcd) for WT, whereas the 6xKO, 11xKO and 14xKO cell lines were reduced to 9.9, 5.7 and 5.6 pcd, respectively (Fig. 3C ). Specific HCP productivity was found to be reduced by 27%, 58% and 59% for the 6xKO, 11xKO
and 14xKO cell lines, respectively, as compared to WT (Fig. 3D) . Besides the improvements in growth characteristics during batch cultivation, we encountered an unexpectedly high reduction in HCP content. As it could be argued that the HCP-reduced phenotype is an artifact of the knockout procedure, we determined the HCP content of unrelated cell lines harbouring multiple knockouts generated using the same procedure.
No significant decrease in HCP content of WT CHO-S and the knockout cell lines is observed ( Fig. S1 and accompanying text) , showing that the HCP-reduced phenotype is specifically caused by the removal of our targeted proteins. To gain a better understanding of the impact of these knockouts, we measured several basic cell properties and established whether mAb productivity was affected. (HCP pcd). Specific HCP production was normalized to the levels detected in WT. Mean and standard deviation of three technical replicates are shown. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test (*** P ≤ 0.001, **** P ≤ 0.0001).
Antibody-producing knockout cell lines display higher productivity and less total HCCF protein content. To assess several basic cell properties and protein productivity, we generated stable pools expressing the monoclonal antibody Rituximab (Rit). We cultivated the WT, WT Rit, 6xKO Rit, 11xKO Rit, and 14xKO Rit cell lines for 4 days in shake flasks and collected HCCF and cell pellets. We analyzed HCP content, protein content of HCCF and cells, cell size, transfection efficiency, antibody staining efficiency, and Rituximab titer (Fig. 4 and Fig. S2 ). The HCP-reduced phenotype was observed as Rituximab titer (E) of WT (black), WT Rit (red), 6xKO Rit (green), 11xKO Rit (blue), and 14xKO Rit (grey) cell lines. All properties were measured after cultivation for four days in shake flasks. Mean and standard deviation of three technical replicates are shown for all experiments except for the staining efficiency determination. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test (ns = not significant, *** P ≤ 0.001, **** P ≤ 0.0001).
before ( Fig. S2B) , while VCD was similar for all cell lines (Fig. S2A) . The total protein content of the HCCF obtained from the knockout cell lines was significantly reduced by approximately 50% (Fig. 4A) , while cell size was reduced from 13.4 µm to 12.5 µm (Fig.   S2B ). The protein content per cell remained unchanged at approximately 150 pg protein per cell (Fig. 4B) , which corresponds well with published values using a CHO-K1 cell line 28 . Antibody productivity in cell pools was assayed in two ways: 1) by an antibody staining method and subsequent FACS analysis (Fig. 4C) and 2) by biolayer interferometry (Fig. 4D) . The knockout cell lines displayed higher productivity as compared to WT using both methods. Whereas productivity increased with the number of knockouts using the staining method, it is only increased until the 11xKO cell line using biolayer interferometry.
Transfection efficiency was similar for all cell lines (Fig. S2D ). Based on these results, we processing. In addition, we wanted to assure that high producers could be generated using the knockout cell lines and that these retained the HCP-reduced phenotype.
Media screening using the Ambr bioreactor revealed that high-producing mAb clones could be selected from all knockout mutants (Fig. S3) . As productivity was most comparable across mutants in FortiCHO medium, we selected this medium to scale up cultivation in a DASGIP bioreactor (Fig. 5) . To limit the contribution of lysed cells to HCP content in the downstream process, we harvested when the first culture dropped below 90% viability (Fig. 5A, arrow) . Maximum VCD of WT Rit and the 11xKO Rit cell lines were comparable (Fig. 5A) , while the VCD of the 6xKO Rit cell line was approximately 50%
lower (also observed in the Ambr bioreactor). However, Rituximab titer at harvest (Fig. 5B) of the 6xKO Rit cell line was comparable to WT Rit, while the 11xKO Rit cell line produced approximately 40% less. HCP titer reduction of the 6xKO Rit and 11xKO Rit cell lines was even more pronounced under these circumstances. Whereas the WT Rit cell line produces 1080 µg/mL HCP, the 6xKO and 11xKO cell lines behave similarly and produce approximately 200 µg/mL HCP (Fig. 5C ). Specific HCP productivity was 19.7 pcd for WT Rit, whereas the 6xKO Rit and 11xKO Rit cell lines were reduced to 5.9 and 4.8 pcd, respectively (Fig. 5D) . To emphasize the substantial improvement in product purity, we calculated the mAb/HCP ratio, which is improved 7-fold in the 6xKO Rit cell line and 2-fold in the 11xKO cell line (Fig. 5E ). Importantly, under controlled cultivation, our knockout cell lines retain the strongly HCP-reduced phenotype.
Knockout cell lines show reduced HCP content throughout a mAb purification process. To assess the effect of the knockouts on downstream purification, we performed protein A affinity chromatography, followed by cation exchange chromatography (CIEX) and anion exchange chromatography (AIEX) (see Fig. S4 ). Samples were collected after every chromatographic step and were analyzed with respect to mAb concentration and HCP content. Using these data, we calculated mAb purification efficiency, HCP content per mg mAb in ppm, and HCP log reduction values (LRV) ( Table 2) . Purification efficiency ranges from 35% to 55% and total HCP LRV of the process ranges from 4.4 to 5.8. HCP content after three chromatographic steps was 45 ppm, 18 ppm and 3 ppm for the WT Rit, 6xKO cell and 11xKO cell lines, respectively. In addition to the decrease in HCP content in the 11xKO cell line throughout mAb purification, we also observed an increase in HCP clearance during protein A chromatography of one order of magnitude. We conclude that the HCP-reduced phenotype is maintained throughout a representative downstream process.
Discussion
The yield of recombinant proteins during biomanufacturing has steadily increased over the past decades. Thus, downstream processing has become a bottleneck in biotherapeutic production 29 . Efforts to alleviate this have mostly focused on innovations in process design to improve downstream processing capacity, speed, and economics 30, 31 . It has also been suggested that cell line engineering could be used to reduce or remove problematic HCPs, lessening the need for additional purification steps 6, 32 . Indeed, researchers have specifically removed unwanted proteins from CHO cell lines that affect product quality 1, 2, 11, 12 . In addition, it has recently been shown that depletion of a highly abundant mRNA encoding a non-essential protein can improve growth and product titer, indicating that it is possible to free up energetic and secretory resources by rational cell line engineering strategies 33 . This observation was supported by a model of the secretory pathway, which was able to accurately predict the increase in growth and protein productivity 19 . These studies have so far been limited to single engineering targets, but could easily be applied on a larger scale. Although different in approach, a recent paper pioneers the use of inducible downregulation of non-product related protein expression leading to an increase in the purity of the biopharmaceutical product 34 . Knowledge-based decisions can support purity-by-design approaches and could lead to easier downstream purification processing.
Here, we hypothesized that removal of HCPs by targeted gene disruption will lead to improvements in cell growth, secretory pathway capacity, and DSP. We used computational modeling to demonstrate that CHO cells spend substantial resources on the host cell secretome. We proceeded with the removal of 14 HCPs, which were more highly abundant in CHO HCCF. We also prioritized targets that can be difficult-to-remove or that influence product quality. Surprisingly we found the removal of these 14 HCPs led to a substantial decrease in HCP content of up to 70% and HCCF total protein content of up to 50%. The observed phenotype persists under controlled cultivation and is specifically caused by the knockouts. Importantly, the ability to generate high mAb producers was not perturbed.
Improvements in product purity will considerably facilitate the purification of mAbs to acceptable HCP levels, especially in those situations where HCPs form a challenge in the purification or quality of a biotherapeutic protein.
It is tempting to speculate that one of the ion exchange chromatography steps could be omitted from the downstream purification process. However, besides the removal of HCP impurities, ion exchange chromatography is also used to reduce high molecular weight aggregates, charge-variants, residual DNA, leached Protein A and viral particles 35 . It remains to be seen whether two chromatographic steps can bring other product-and process-related impurities within regulatory requirements. The results presented here certainly warrant a detailed analysis of the HCPreduced cell lines under industrial mAb production conditions with respect to growth, production and mAb critical quality attributes.
Conclusion
Through a multiplex genome editing approach here, we successfully removed more than half of the HCPs in CHO cells by mass. This demonstration highlights that large-scale genome editing in mammalian cells can be done for bioproduction, and can have benefits throughout the bioproduction process. In particular, such efforts can be effectively used to make clean CHO cells by eliminating many undesirable HCPs 6 and retroviral-like particles 36 that currently require extensive purification strategies. Through this, one may obtain higher quality drugs and produce these at lower costs. 
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Text to figure S1
A possible explanation for the HCP-reduced phenotypes observed in this study is that the creation of knockouts selects for faster-growing cells. As cells have go through a singlecell stage where survival rates are low, a selective pressure for better growth is imposed.
It may thus be possible that the phenotype is not caused by specific knockouts, but is a more general effect of global downregulation of costly, secretory proteins. We quantified the HCP content of cell lines generated in an independent study addressing glycosylation except for the transfection efficiency determination. Statistical analysis was performed using oneway ANOVA followed by Tukey's post-hoc test (ns = not significant, **** P ≤ 0.0001).
Text to figure S3
Growth characteristics and productivity of the knockout mutants were evaluated in an Ambr bioreactor using FortiCHO, ActiPro and OptiCHO media. Productivity was found to be highest in the 6xKO Rit cell line in OptiCHO medium (Fig. S3C, right panel) . VCD of all clones cultured in this medium reached a maximum level of approximately 15 million cells per milliliter. While the VCD of WT Rit and 11xKO dropped after 8 days in culture, VCD of 6xKO Rit was constant for the remainder of the experiment (Fig. S3A, right panel) . In addition, viability of the 6xKO Rit cell line remained higher than the other cell lines in this medium (Fig. S3B, right panel) , indicating prolonged culture longevity. In ActiPro medium, we observed low VCD and productivity of both knockout cell lines as compared to WT Rit ( Fig. S3A and S3C, center panels) . In FortiCHO medium, the productivity of all cell lines was comparable, even though the cell density of WT Rit was higher than the 6xKO Rit and 11xKO Rit cell lines (Fig. S3A and S3C , left panels). Considerable differences in cell density, viability and titer were observed depending on the culture medium. These data show that high mAb production can be achieved in our knockout cell lines. 
